Clevidipine is a dihydropyridine L-type calcium channel blocker used to lower blood pressure when oral antihypertensive therapy is not feasible or not desirable.
- Mechanism
- Curator reviewed
Possibly by deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum, clevidipine inhibits the influx of extracellular calcium across both the myocardial and vascular smooth muscle cell membranes. The resultant inhibition of the contractile processes of the myocardial smooth muscle cells leads to dilation of the coronary and systemic arteries and improved oxygen delivery to the myocardial tissue.
- Primary indication
- For the reduction of blood pressure when when oral antihypertensive therapy is not feasible or not desirable.Curator reviewed · 1 structured indication
- Formula / weight
- C21H23Cl2NO6 · 456.316 g/mol (avg)
- First approval
- Canada, 2016 · United States, 2008
- Also known as
- Clevidipine butyrate
- Code names
- H-324/38
- Brand names
Resolves to
KPBZROQVTHLCDU-UHFFFAOYSA-NSMILESCCCC(=O)OCOC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC(Cl)=C1Cl)C(=O)OCWhat you can answer from here — as of September 12, 2026
Which drugs share a target with Clevidipine, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account